Cytokine dysbalance in type 2 diabetes mellitus patients with prior myocardial infarction
DOI:
https://doi.org/10.21856/j-PEP.2016.4.01Keywords:
type 2 diabetes mellitus, postinfarction cardiosclerosis, cytokine dysbalanceAbstract
he article presents the results of the study of C-reactive protein, interleukin-6, tumor necrosis factor-α and interleukin-10 levels in postmyocardial infarction patients with type 2 diabetes mellitus. It was identified significantly higher concentrations of C-reactive protein, proinflammatory interleukin-6 and tumor necrosis factor-α and anti-inflammatory interleukin-10 in comparison with the control group. The study found that the combination of postinfarction cardiosclerosis and type 2 diabetes mellitus shows higher degree of activity of markers of systemic inflammation than in isolated course of disease, when identical anti-inflammatory protection. The data shows that the blood glucose levels directly affect the concentration of C-reactive protein and interleukin-10, whereas insulin resistance directly depends on the activity of inflammation markers.
References
Hu Y, Zhou X, Guo DH, et al. Int J Endocrinol Metab 2016; 14 (1): e34400. http://dx.doi.org/10.5812/ijem.34400
Zozulinska D, Wierusz-Wysocka B. Diabetes Res Clin Pract 2006; 74(2):12-16. doi: http://dx.doi.org/10.1016/j.diabres.2006.06.007
Senn J, Klover P, Nowak I, et al. Diabetes 2002; 51:3391-3399. doi: http://dx.doi.org/10.2337/diabetes.51.12.3391
Miyazaki Y, Pipek R, Mandarino LJ, et al. J. Obes Relat Metab Disord 2003; 27:88-94. doi: http://dx.doi.org/10.1038/sj.ijo.0802187
Greenberg AS, McDaniel ML. Europ J Clin Invest 2002; 32(3):24-34. doi: http://dx.doi.org/10.1046/j.1365-2362.32.s3.4.x
Pavlikova EP, Merai IA. Kardiologija 2003; 8:68-71.
Gontsariuk DO, Khristich TM, Fediv OI, et al. Praktychna Angiologija 2012; 3/4:26-30.
Kravchun PP, Bilovol OM. Liky Ukrai’ny 2010; 8(144):101-103.
Martin-Timon I, Sevillano-Collantes C, Segura-Galindo A, et al. World J Diabetes 2014; 5(4):444-470. doi: http://dx.doi.org/10.4239/wjd.v5.i4.444
Scholten BJ, Reinhard H, Hansen TW, et al. J Diabetes Complications 2016; 30(2):248-255. doi: http://dx.doi.org/10.1016/j.jdiacomp.2015.11.005
Zhuravleva LV, Sokolnikova NV. Mezhdunar Endokrinol Zhurn 2012; 5(45):13-17.
Borowska M, Dworacka M, Wesolowska A, et al. Pharmacology 2016; 97(3-4):189-194. doi: http://dx.doi.org/10.1159/000443897
Moretini M, Storm F, Sacchetti M, et al. Prev Med Rep 2015; 2:538-547. doi: http://dx.doi.org/10.1016/j.pmedr.2015.06.012
Krysiak R, Gdula-Dymek A, Marek B, Okopien B. Endokrynologia Polska 2016; 67(2):190-196. doi: http://dx.doi.org/10.5603/EP.a2016.0021
Francisco CO, Catai AM, Moura-Tonello SC, et al. Braz J Med Biol Res. 2016; 49(4):e5062.
Gorshunska MYu, Krasova NS, Karachentsev YuI, et al. Probl Endokryn Patol 2009; 1:5-11.
Li Y, Ni J, Guo R, et al. BioMed Res Intern 2016; 2016:8734827. doi: http://dx.doi.org/10.1155/2016/8734827
Barry JC, Shakibakho S, Durrer C, et al. Sci Rep 2016; 6:21244. doi: http://dx.doi.org/10.1038/srep21244